

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/923,117	08/06/2001	William F. McKay	4002-2804	9544
75	590 01/27/2005	•	EXAM	INER
Kenneth A. Gandy			BONDERER, DAVID A	
Woodard Emhart Naughton Moriarty & McNett Suite 3700			ART UNIT	PAPER NUMBER
111 Moument Circle			3732	
Indianapolis, IN 46204-5137			DATE MAILED: 01/27/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No _:	Applicant(s)				
Advisory Action	09/923,117	MCKAY, WILLIAM F.				
Advisory Action	Examiner	Art Unit				
	D. Austin Bonderer	3732				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
THE REPLY FILED 14 December 2004 FAILS TO PLACE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (condition for allowance; (2) a timely filed Notice of Appel Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applic 1) a timely filed amendment whi al (with appeal fee); or (3) a time	cation. A proper reply to a ch places the application in				
PERIOD FOR RE	EPLY [check either a) or b)]					
a) The period for reply expiresmonths from the mailing of						
b) The period for reply expires on: (1) the mailing date of this Advevent, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The dahave been filed is the date for purposes of determining the period of exten 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three moderned patent term adjustment. See 37 CFR 1.704(b).	an SIX MONTHS from the mailing date o FILED WITHIN TWO MONTHS OF THI te on which the petition under 37 CFR 1.1 sion and the corresponding amount of the distatutory period for reply originally set in	f the final rejection. E FINAL REJECTION. See MPEP 136(a) and the appropriate extension fee fee. The appropriate extension fee under the final Office action; or (2) as set forth in				
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
$2. \boxtimes$ The proposed amendment(s) will not be entered b	ecause:					
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application issues for appeal; and/or	in better form for appeal by mat	erially reducing or simplifying the				
(d) they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: See Continuation Sheet.						
3. Applicant's reply has overcome the following rejection(s):						
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	l be allowable if submitted in a s	separate, timely filed amendment				
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:						
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly				
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w						
The status of the claim(s) is (or will be) as follows:	:					
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected:						
Claim(s) withdrawn from consideration:						
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
PE	CRO PHILOGENE					

Continuation of 2. NOTE: Claims 10 and 17 that are subject of the amendment were addressed in the previous two actions. The rejection plainly states that it would have been obvious to one having ordinary skill in the art at the time of the invention was made to use the specific claimed bone morphogenetic protein, since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended us as a matter of obvious design choice. In re Leshin, 125 USPQ 416. The only possible contention could be that the use of the clamed proteins where not known in the art at the time of invention. However, US 6,352,972 clearly shows the use of BMP series morphogenetic proteins for bone growth as early as June 3, 1997. It is clear that the BMP protein was within the knowledge of one of ordinary skill in the art at the time of the instant invention.

PEDRO PI WE DESIVE PRIMARY EXAMINER